Screener
MoonLake Immunotherapeutics MLTX Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 8:55 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001821586-26-000007
| (in thousands, except share and per share data) | March 31, 2026 (Unaudited) | December 31, 2025 |
|---|---|---|
| Short-term marketable debt securities | 59,431 | 59,451 |
| Other receivables | 5,763 | 4,869 |
| Prepaid expenses | 32,957 | 22,857 |
| Total current assets | 396,641 | 421,694 |
| Non-current assets | ||
| Operating lease right-of-use assets | 1,857 | 1,566 |
| Property and equipment, net | 532 | 577 |
| Other non-current assets | 1,344 | 596 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is MoonLake Immunotherapeutics's total current assets?
- MoonLake Immunotherapeutics (MLTX) reported total current assets of $396.64M in Q1 2026.
- How has MoonLake Immunotherapeutics's total current assets changed year-over-year?
- MoonLake Immunotherapeutics's total current assets decreased by 21.7% year-over-year, from $506.26M to $396.64M.
- What is the long-term trend for MoonLake Immunotherapeutics's total current assets?
- Over 5 years (2020 to 2025), MoonLake Immunotherapeutics's total current assets has grown at a 204.2% compound annual growth rate (CAGR), from $1.62M to $421.69M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about MoonLake Immunotherapeutics's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude